See more : Great-West Lifeco Inc. (GRWTF) Income Statement Analysis – Financial Results
Complete financial analysis of NextCell Pharma AB (NXTCL.ST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NextCell Pharma AB, a leading company in the Biotechnology industry within the Healthcare sector.
- International Data Management Limited (IDM.BO) Income Statement Analysis – Financial Results
- SureNano Science Ltd. (SURE.CN) Income Statement Analysis – Financial Results
- XOMA Corporation (XOMA) Income Statement Analysis – Financial Results
- Subsea 7 S.A. (SUBCY) Income Statement Analysis – Financial Results
- DREAMTECH Co., Ltd. (192650.KS) Income Statement Analysis – Financial Results
NextCell Pharma AB (NXTCL.ST)
About NextCell Pharma AB
NextCell Pharma AB, a biopharmaceutical company, engages in the research and development of novel stem cell therapies in Sweden. The company develops ProTrans, a drug candidate comprising stem cells primarily for treating autoimmune and inflammatory diseases. It also provides Cellaviva, a stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue. NextCell Pharma AB was incorporated in 2014 and is based in Huddinge, Sweden.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.66M | 10.11M | 5.59M | 3.91M | 3.56M | 1.81M | 655.41K | 517.20K | 809.01K | 6.96K |
| Cost of Revenue | 54.41M | 11.00M | 27.85M | 18.44M | 13.94M | 15.82M | 8.83M | 3.19M | 5.87M | 5.05M |
| Gross Profit | -43.75M | -884.83K | -22.26M | -14.53M | -10.37M | -14.01M | -8.17M | -2.67M | -5.06M | -5.04M |
| Gross Profit Ratio | -410.21% | -8.75% | -398.31% | -371.36% | -291.00% | -773.13% | -1,247.08% | -516.90% | -625.84% | -72,434.89% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 8.50M | 7.17M | 10.21M | 4.85M | 6.53M | 5.13M | 5.05M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | -576.02K | 43.47M | 31.85M | 8.50M | 7.17M | 10.21M | 4.85M | 6.53M | 5.13M | 5.05M |
| Other Expenses | 0.00 | 40.12M | 12.76M | 1.88M | 156.36K | -2.77M | 5.87M | 4.06M | 6.36M | 5.38M |
| Operating Expenses | -576.02K | 40.12M | 12.76M | 10.38M | 7.33M | 7.44M | 5.87M | 10.59M | 6.36M | 5.38M |
| Cost & Expenses | 53.84M | 51.12M | 40.61M | 28.82M | 21.27M | 23.27M | 14.70M | 13.78M | 12.24M | 10.43M |
| Interest Income | 1.21M | 1.19M | 483.10K | 271.84K | 30.51K | 10.63K | 30.64K | 17.54K | 13.98K | 133.30K |
| Interest Expense | 1.36K | 2.81K | 13.53K | 7.57K | 8.84K | 7.79K | 16.22K | 1.90K | 1.27K | 1.38K |
| Depreciation & Amortization | 974.67K | 447.88K | 457.34K | 437.02K | 397.10K | 348.26K | 298.72K | 298.72K | 298.72K | 414.62K |
| EBITDA | -40.99M | -39.36M | -34.10M | -24.21M | -17.28M | -17.64M | -13.73M | -12.95M | -11.11M | -9.87M |
| EBITDA Ratio | -384.31% | -389.19% | -609.85% | -616.36% | -484.61% | -1,164.06% | -2,092.93% | -2,502.81% | -1,373.71% | -141,863.78% |
| Operating Income | -43.17M | -41.00M | -35.02M | -24.82M | -17.70M | -21.45M | -14.05M | -13.26M | -11.43M | -10.42M |
| Operating Income Ratio | -404.81% | -405.42% | -626.68% | -634.48% | -496.60% | -1,183.86% | -2,143.19% | -2,563.96% | -1,412.36% | -149,736.24% |
| Total Other Income/Expenses | 1.21M | 1.19M | 469.57K | 264.27K | 21.67K | 2.84K | 14.42K | 15.65K | 12.71K | 131.93K |
| Income Before Tax | -41.96M | -39.81M | -34.55M | -24.56M | -17.68M | -21.45M | -14.03M | -13.25M | -11.41M | -10.29M |
| Income Before Tax Ratio | -393.45% | -393.65% | -618.28% | -627.73% | -495.99% | -1,183.71% | -2,140.98% | -2,560.93% | -1,410.79% | -147,840.73% |
| Income Tax Expense | 0.00 | 1.19M | -469.57K | 7.57K | 8.84K | 7.79K | 30.64K | 17.54K | 13.98K | 133.30K |
| Net Income | -41.96M | -39.81M | -34.08M | -24.56M | -17.69M | -21.46M | -14.03M | -13.25M | -11.41M | -10.29M |
| Net Income Ratio | -393.45% | -393.65% | -609.88% | -627.92% | -496.24% | -1,184.14% | -2,140.98% | -2,560.93% | -1,410.79% | -147,840.73% |
| EPS | -1.03 | -1.16 | -1.01 | -0.81 | -0.89 | -1.45 | -1.65 | -3.34 | -4.37 | -4.14 |
| EPS Diluted | -1.03 | -1.16 | -1.01 | -0.81 | -0.89 | -1.45 | -1.65 | -3.34 | -4.37 | -4.14 |
| Weighted Avg Shares Out | 40.81M | 34.38M | 34.38M | 30.41M | 19.86M | 12.38M | 8.51M | 3.97M | 2.61M | 2.49M |
| Weighted Avg Shares Out (Dil) | 40.81M | 34.38M | 34.38M | 30.41M | 19.86M | 12.38M | 8.51M | 3.97M | 2.61M | 5.01M |
Source: https://incomestatements.info
Category: Stock Reports